Have a personal or library account? Click to login
Long-term results of Boston keratoprosthesis surgery in Polish patients Cover

Long-term results of Boston keratoprosthesis surgery in Polish patients

Open Access
|Mar 2022

Abstract

Introduction

To evaluate the long-term (10 year) outcomes of Boston type 1 keratoprosthesis (BKPro; Massachusetts Eye and Ear Infirmary, Boston, MA) surgery performed in 6 Polish patients.

Materials and Methods

6 eyes of 6 patients (1 female and 5 males; mean age 49,5±6,34 years) were qualified for the surgery. Indications for BKPro surgery in the study group included: corneal graft failure (3 patients), chemical ocular burns (2 patients), and post-herpetic keratitis vascularized leucoma (1 patient). Visual acuity, slit-lamp examination with ocular surface assessment, anterior segment optical coherence tomography (AS OCT), fundoscopy, and intraocular digital pressure measurement were performed at each visit.

Results

Retention of keratoprosthesis was achieved in all patients during the follow-up period. At last recorded visits VA≥0,2 was observed in 3 patients, LP in one patient and NLP in 2 patients. The complications which occurred in our case series were: glaucoma (4 patients preoperatively, 6 patients postoperatively), retroprosthetic membrane formation (1 patient), epimacular membrane formation (2 patients) and severe Meibomian Gland Dysfunction (3 patients). OCT analysis allowed imaging of anterior iris synechiae, AGV tube, protrusion of the BKPro and retroprosthetic membrane not visible on the slit lamp examination.

Conclusions

BKPro surgery should be considered as a surgery of choice in patients who have high risk of PK failure. OCT plays a role in anterior eye segment monitoring and detection of complications not visible on the slit lamp examination in the follow up period. Implementing the dry eye disease treatment should be recommended in all patients undergoing BKPro surgery.

Language: English
Page range: 1 - 10
Submitted on: Feb 23, 2021
Accepted on: Oct 12, 2021
Published on: Mar 14, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2022 Anna Nowińska, Dariusz Dobrowolski, Ewa Wróblewska-Czajka, Ula V Jurkunas, Edward Wylęgała, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.